Burgess et al J Cell Biol vol. 111 2129-2138, 1990.* |
Lazar et al Mol Cell Biol vol. 8(3):1247-1252, Mar. 1988.* |
Acland et al Nature vol. 343:662-665, 1990.* |
Zhang et al Nature vol. 383:168-172, 1996.* |
Kurokawa et al., “The oncoprotein Evi-1 represses TGF-β signalling by inhibiting Smad3,” Nature, vol. 394, No. 6688, pp. 92-96 (1998). |
Imamura et al., “Smad6 inhibits signalling by the TGF-β superfamily,” Nature, vol. 389, No. 6651, pp. 622-626 (1997). |
Nakao et al., “Identification of Smad7, a TGFβ-inducilble antagonist of TGF-α signalling,” Nature, vol. 389, No. 6651, pp. 631-635 (1997). |
Tsukazaki et al., “SARA, a FYVE Domain Protein that Recruits Smad2 to the TGFβ Receptor,” Cell, vol. 95, No. 6, pp. 779-791 (1998). |
Baer et al., “Transforming growth factor betas and their receptors in human liver cirrhosis,” European Jour. of Gastroenterology and Hepatology, vol. 10, No. 12, pp. 1031-1039 (1998). |
Ward et al., “Vascular types I and II transforming growth factor-beta receptor expression: differential dependency on tyrosine kinases during induction by TGF-β,” FEBS Lett., pp. 197-200 (1998). |
Chen et al., “Suppression of transforming growth factor-β-induced apoptosis through a phosphatidylinositol 3-kinase/Akt-dependent pathway,” Oncogene, vol. 17, No. 15, pp. 1959-1968 (1998). |
Stockwell et al., “TGF-62 -signaling with small molecule FKBP12 antagonists that bind myristoylated FKBP12-TGF-β type 1 receptor fusion proteins,” Chem. & Bio., vol. 5, No. 7, pp. 385-395 (1998). |
Goumans et al., “Mouse embryonic stem cells with aberrant transforming growth factor β signalling exhibit impaired differentiation in vitro and in vivo,” Differentiation, vol. 63, No. 3, pp. 101-113 (1998). |
Ward et al., “Inhibitory effects of tranilast on expression of transforming growth factor-β isoforms and receptors in injured arteries,” Atherosclerosis, vol. 137, No. 2, pp. 267-275 (1998). |
Goto et al., “a single missense mutant of Smad3 inhibits activation of both Smad2 and Smad3, and has a dominant negative effect on TGF-β signals,” FEBS Lett., vol. 430, No. 3, pp. 201-204 (1998). |
Shen et al., “TGF-β-induced Phosphorylation of Smad3 Regulates Its Interation with Coactivator p300/CREB-binding Protein,” Molecular Biology of the Cell, vol. 9, No. 12, pp. 3309-3319 (1998). |
Ali et al, “Angiotensin-Converting Enzyme Inhibition Attentuates Proteinuria and Renal TGF-β1 mRNA Expression in Rats with Chronic Renal Disease,” Pharmacology, vol. 57, No. 1, pp. 20-27 (1998). |
Coppa et al., “Restored Expression of Transforming Growth Factor β Type II Receptor in k-ras-Transformed Thyroid Cells, TGFβ-Resistant, Reverts Their Malignant Phenotype,” Journal of Cellular Physiology, vol. 172, No. 2, pp. 200-208 (1997). |
Sekelsky et al., Genetics, vol. 139, pp. 1347-1358. (3/95). |
Sulston et al., Nature, vol. 356, pp. 37-41. (3/92). |
Wilson et al., Nature, vol. 368, pp. 32-38. (3/94). |
Howard et al., Cell, vol. 71, pp. 637-647 (11/92). |
Reeck et al., Cell, vol. 50, pp. 667 (8/87). |
Lewin et al., Science, vol. 237, pp. 1570 (1987). |
Eppert et al., “MADR2 Maps to 18q21 and Encodes a TGFβ-Regulated MAD-Related Protein that is Functionally Mutated in Colorectal Carcinoma”, Cell, vol. 86, pp. 543-552 (1996). |
GenBank Accession No. U68018, Zhang, et al., Jul. 2, 1999 (Rel. 60, Last updated, Version 4). |